What safety considerations are important when prescribing benzodiazepines for sleep or anxiety in the context of respiratory disease or COPD?

• A. They are completely safe with respect to respiratory function.
• B. They improve respiratory drive and are first-line therapy.
• C. They do not affect respiration and can be used freely.
• D. They increase risk of respiratory depression and sedation; use with caution; prefer non-BZD therapies or short-term use; monitor daytime somnolence.

Answer: (D)

In this context, the key safety concern with benzodiazepines is their tendency to depress the central nervous system and blunt the respiratory drive. For someone with COPD or other respiratory disease, that can worsen gas exchange, increase the risk of hypoventilation, and heighten nocturnal hypoxemia or CO2 retention, especially during sleep. Sedation also extends into the day, producing somnolence, impaired coordination, and cognitive slowing, which raises the risk of falls and accidents and can interfere with daytime functioning.

Because of these risks, use benzodiazepines with great caution in respiratory disease. The safer approach emphasizes non-drug strategies for sleep and anxiety when possible—sleep hygiene or cognitive behavioral therapy for insomnia, and non-sedating or other pharmacologic options for anxiety. If a benzodiazepine is considered, it should be for the shortest possible duration, at the lowest effective dose, and with careful monitoring of daytime sedation and respiratory status. Avoid combining with other CNS depressants and, when feasible, opt for non-benzodiazepine therapies or very short-term use with close follow-up.